SEC 13F Intelligence

Skandinaviska Enskilda Banken AB (Publ) / ALXN

Skandinaviska Enskilda Banken AB (Publ)’s Alexion Pharmaceuticals Inc Position

Does Skandinaviska Enskilda Banken AB (Publ) own Alexion Pharmaceuticals Inc (ALXN)? Not currently — the last reported position was 182.8K shares worth $34M in Q2 2021; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$34M
Q2 2021
Shares
182.8K
% of Portfolio
+0.21%
Quarters Held
11
position exited

Position History ALXN

Reported value by quarter
Q4 ’18: $13MQ4 ’18Q1 ’19: $17MQ2 ’19: $18MQ2 ’19Q3 ’19: $12MQ4 ’19: $14MQ4 ’19Q1 ’20: $10MQ2 ’20: $16MQ2 ’20Q3 ’20: $44MQ4 ’20: $82MQ4 ’20Q1 ’21: $44MQ2 ’21: $34MQ2 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2021182.8K$34M+0.21%
Q1 2021287.3K$44M+0.29%
Q4 2020526.5K$82M+0.57%
Q3 2020386.4K$44M+0.32%
Q2 2020144.6K$16M+0.13%
Q1 2020113.4K$10M+0.11%
Q4 2019125.5K$14M+0.11%
Q3 2019120.8K$12M+0.10%
Q2 2019137.5K$18M+0.16%
Q1 2019128.0K$17M+0.16%
Q4 2018134.8K$13M+0.12%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Skandinaviska Enskilda Banken AB (Publ)’s full portfolio or all institutional holders of ALXN.